Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hepatitis C Virus
100%
Cancer Patients
70%
In Cancer
50%
Sustained Virological Response
44%
Hepatitis C Virus Screening
30%
Direct-acting Antivirals
30%
Anti-hepatitis C Virus
30%
SVR12
30%
Prospective Observational Study
30%
Tertiary Cancer Center
26%
Vancomycin-resistant Enterococcus Faecium (VREfm)
26%
Sofosbuvir
23%
HIV-infected Patients
23%
Chronic Hepatitis C Virus Infection
21%
Response Rate
19%
Acute Hepatitis C
16%
Clinically Significant
15%
Hepatitis C Virus Infection
15%
Direct-acting Antiviral Therapy
14%
Oncological Outcomes
14%
Follicular Lymphoma
13%
Genitourinary Cancer
13%
Anticancer Therapy
13%
Baloxavir
13%
Humoral Immunity
13%
Diphtheria
13%
Pneumococcus
13%
Daptomycin
13%
Immune Therapy
13%
Concurrent Malignancy
13%
Hospitalized Patients
13%
Tetanus
13%
Interferon-gamma Release Assay
13%
Patients with Cancer
13%
Tuberculosis Diagnosis
13%
CD4 Cell Count
13%
Phage
13%
Direct-acting
13%
Humoral Antibody Response
13%
Vaccine Impact
13%
Hepatitis C
13%
Galleria Mellonella
13%
Salvage Therapy
13%
Novel Treatments
13%
Severe Influenza
13%
Mycobacterium Tuberculosis (M. tb)
13%
Chimeric Antigen Receptor T Cells (CAR-T)
13%
Bacteriophage
13%
Wax Moth
13%
Functional Characterization
13%
Immunology and Microbiology
Hepatitis C Virus
65%
Hepatitis C
41%
Infectious Disease
40%
Infection
40%
Vancomycin-Resistant Enterococcus
26%
Hematopoietic Cell
18%
Effector Cell
14%
Influenza
13%
CD4 Lymphocyte Count
13%
High Risk Population
13%
Humoral Antibody
13%
Streptococcus pneumonia
13%
Chimeric Antigen Receptor T-Cell Therapy
13%
Antibody Response
13%
Galleria mellonella
13%
Humoral Immunity
13%
Bacteriophage
13%
Cytomegalovirus Infection
13%
CD4 Lymphocyte Percentage
10%
Ribonucleic Acid
7%
Ribavirin
6%
Enterococcus faecium
6%
Screening Test
6%
Sofosbuvir
6%
NS5A
6%
Medicine and Dentistry
Hepatitis C Virus
65%
Malignant Neoplasm
62%
Hepatitis C
27%
Observational Study
26%
Chronic Hepatitis C
16%
Chimeric Antigen Receptor T-Cell Immunotherapy
13%
Cross Sectional Study
13%
Urogenital Tract Cancer
13%
Cancer Treatment
13%
Sofosbuvir
13%
COVID-19
13%
Cytomegalovirus Infection
13%
Case-Control Study
13%
Interferon
13%
Release Assay
13%
Salvage Therapy
13%
Prospective Study
13%
Tuberculosis
13%
Cancer
8%
Prevalence
6%
Electronic Health Record
6%
Adverse Event
6%
Hepatocellular Carcinoma
6%
Hazard Ratio
5%